BRIEF published on 12/11/2025 at 23:05, 7 months 28 days ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 7 months 28 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 7 months 28 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 8 months 20 days ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 8 months 20 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 8 months 20 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 8 months 26 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 8 months 26 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 8 months 26 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 9 months 30 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 08/07/2026 at 23:15, 1 day 23 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 1 day 23 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 1 day 23 hours ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 2 days ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/09/2026 at 15:05, 7 hours 14 minutes ago GearUP and Escape from Tarkov Partner to Enhance Online Gaming Experience for the New Season
Published on 08/09/2026 at 00:01, 22 hours 18 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 08/08/2026 at 16:25, 1 day 5 hours ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 1 day 22 hours ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 2 days 2 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 18:54, 2 days 3 hours ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 2 days 3 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days 3 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 2 days 3 hours ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 2 days 4 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
